IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0967179
(2013-08-14)
|
| 등록번호 |
US-8633162
(2014-01-21)
|
|
발명자
/ 주소 |
- Acheampong, Andrew
- Tang-Liu, Diane D.
- Chang, James N.
- Power, David F.
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
5 인용 특허 :
94 |
초록
▼
Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1 % by weight of the composition. Th
Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1 % by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
대표청구항
▼
1. A method of treating dry eye disease, the method comprising topically administering to the eye of a human in need thereof an emulsion at a frequency of twice a day, wherein the emulsion comprises cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate c
1. A method of treating dry eye disease, the method comprising topically administering to the eye of a human in need thereof an emulsion at a frequency of twice a day, wherein the emulsion comprises cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; and wherein the topical ophthalmic emulsion is effective in treating dry eye disease. 2. The method of claim 1, wherein the emulsion further comprises a tonicity agent or a demulcent component. 3. The method of claim 2, wherein the tonicity agent or the demulcent component is glycerine. 4. The method of claim 1, wherein the emulsion further comprises a buffer. 5. The method of claim 4, wherein the buffer is sodium hydroxide. 6. The method of claim 1, wherein the topical ophthalmic emulsion further comprises glycerine and a buffer. 7. The method of claim 1, wherein the emulsion comprises polysorbate 80 in an amount of about 1.0% by weight. 8. The method of claim 1, wherein the emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight. 9. The method of claim 1, wherein the emulsion further comprises glycerine in an amount of about 2.2% by weight and a buffer. 10. The method of claim 9, wherein the buffer is sodium hydroxide. 11. The method of claim 1, wherein, when the emulsion is administered to an eye of a human, the blood of the human has substantially no detectable concentration of cyclosporin A. 12. The method of claim 6, wherein the emulsion has a pH in the range of about 7.2 to about 7.6. 13. The method of claim 1, wherein the emulsion is as substantially therapeutically effective as a second emulsion administered to a human in need thereof at a frequency of twice a day, the second emulsion comprising cyclosporin A in an amount of 0.1% by weight and castor oil in an amount of 1.25% by weight. 14. The method of claim 1, wherein the emulsion achieves at least as much therapeutic effectiveness as a second emulsion administered to a human in need thereof a frequency of twice a day, the second emulsion comprising cyclosporin A in an amount of 0.1% by weight and castor oil in an amount of 1.25% by weight. 15. The method of claim 1, wherein the emulsion breaks down more quickly in the eye of a human, once administered to the eye of the human, thereby reducing vision distortion in the eye of the human as compared to a second emulsion that contains only 50% as much castor oil. 16. The method of claim 1, wherein the emulsion, when administered to the eye of a human, demonstrates a reduction in adverse events in the human, relative to a second emulsion administered to a human in need thereof a frequency of twice a day, the second emulsion comprising cyclosporin A in an amount of 0.1% by weight and castor oil in an amount of 1.25% by weight. 17. The method of claim 16, wherein the adverse events are side effects. 18. A method of reducing side effects in a human being treated for dry eye syndrome, the method comprising the step of topically administering to the eye of the human in need thereof an emulsion at a frequency of twice a day, wherein the emulsion comprises: cyclosporin A in an amount of about 0.05% by weight;castor oil in an amount of about 1.25% by weight;polysorbate 80 in an amount of about 1.0% by weight;acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight;a tonicity component or a demulcent component in an amount of about 2.2% by weight;a buffer; andwater;wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6. 19. The method of claim 18, wherein the buffer is sodium hydroxide. 20. The method of claim 18, wherein the tonicity component or the demulcent component is glycerine. 21. The method of claim 18, wherein, when the emulsion is administered to the eye of a human for treating dry eye syndrome, the blood of the human has substantially no detectable concentration of the cyclosporin A. 22. The method of claim 18, wherein the emulsion is effective in treating dry eye disease. 23. A method of treating dry eye disease, the method comprising the step of topically administering to an eye of a human in need thereof an emulsion at a frequency of twice a day, the emulsion comprising: cyclosporin A in an amount of about 0.05% by weight;castor oil in an amount of about 1.25% by weight;polysorbate 80 in an amount of about 1.0% by weight;acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight;glycerine in an amount of about 2.2% by weight;sodium hydroxide; andwater;wherein the emulsion is effective in treating dry eye disease. 24. The method of claim 23, wherein the emulsion has a pH in the range of about 7.2 to about 7.6.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.